2023
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.
Zelenetz A, Gordon L, Abramson J, Advani R, Andreadis B, Bartlett N, Budde L, Caimi P, Chang J, Christian B, DeVos S, Dholaria B, Fayad L, Habermann T, Hamid M, Hernandez-Ilizaliturri F, Hu B, Kaminski M, Karimi Y, Kelsey C, King R, Krivacic S, LaCasce A, Lim M, Messmer M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts K, Saeed H, Smith S, Svoboda J, Swinnen L, Tuscano J, Vose J, Dwyer M, Sundar H. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023. Journal Of The National Comprehensive Cancer Network 2023, 21: 1118-1131. PMID: 37935098, DOI: 10.6004/jnccn.2023.0057.Peer-Reviewed Original ResearchConceptsB-cell lymphomaMantle cell lymphomaCAR T-cell therapyT-cell therapyTyrosine kinase inhibitorsFollicular lymphomaNCCN guidelinesAnti-CD19 CAR T-cell therapyRefractory B-cell lymphomaTreatment of FLBispecific T-cell engagersBruton tyrosine kinase inhibitorsLarge B-cell lymphomaNCCN Guidelines InsightsRefractory follicular lymphomaNovel immunotherapeutic approachesRelapsed Follicular LymphomaT-cell engagersTreatment landscapeImmunotherapeutic approachesFrontline settingTreatment optionsCell lymphomaLymphomaTherapy
2021
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.
Zelenetz AD, Gordon LI, Chang JE, Christian B, Abramson JS, Advani RH, Bartlett NL, Budde LE, Caimi PF, De Vos S, Dholaria B, Fakhri B, Fayad LE, Glenn MJ, Habermann TM, Hernandez-Ilizaliturri F, Hsi E, Hu B, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Lim M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. Journal Of The National Comprehensive Cancer Network 2021, 19: 1218-1230. PMID: 34781267, DOI: 10.6004/jnccn.2021.0054.Peer-Reviewed Original ResearchConceptsB-cell lymphomaNCCN guidelinesAnti-CD19 CAR T-cell therapyB-cell non-Hodgkin lymphomaCAR T-cell therapyB-cell receptor pathwayLarge B-cell lymphomaNCCN Guidelines InsightsRelapsed/refractoryT-cell therapyNon-Hodgkin lymphomaNovel treatment optionsMantle cell lymphomaAntibody-drug conjugatesR diseaseTherapy optionsTreatment optionsCell lymphomaFollicular lymphomaSmall molecule inhibitorsLymphomaMolecular pathogenesisReceptor pathwayMolecule inhibitorsTherapyPediatric Hodgkin Lymphoma, Version 3.2021.
Flerlage J, Hiniker S, Armenian S, Benya E, Bobbey A, Chang V, Cooper S, Coulter D, Cuglievan B, Hoppe B, Isenalumhe L, Kelly K, Kersun L, Lamble A, Larrier N, Magee J, Oduro K, Pacheco M, Price A, Roberts K, Smith C, Sohani A, Trovillion E, Walling E, Xavier A, Burns J, Campbell M. Pediatric Hodgkin Lymphoma, Version 3.2021. Journal Of The National Comprehensive Cancer Network 2021, 19: 733-754. PMID: 34214968, DOI: 10.6004/jnccn.2021.0027.Peer-Reviewed Original ResearchConceptsPediatric Hodgkin lymphomaClassic Hodgkin lymphomaHodgkin's lymphomaNCCN Clinical Practice GuidelinesClinical practice guidelinesCurrent treatment regimensNCCN guidelinesRefractory settingSystemic therapyCurable formTreatment regimensPrinciples of pathologyDiagnostic evaluationLate effectsPractice guidelinesRadiation therapyTreatment efficacyLymphomaTherapyTreatmentGuidelinesRegimensWorkupCancerStaging
2020
Patterns of Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children’s Oncology Group
Parikh R, Hoppe B, Hodgson D, McCarten K, Pei Q, Cho S, Schwartz C, Cole P, Kelly K, Roberts K. Patterns of Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children’s Oncology Group. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: s36-s37. DOI: 10.1016/j.ijrobp.2020.07.2140.Peer-Reviewed Original Research
2019
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.
Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Bartlett NL, Caimi PF, Chang JE, Chavez JC, Christian B, Fayad LE, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Mehta A, Nademanee A, Rabinovitch R, Reddy N, Reid E, Roberts KB, Smith SD, Snyder ED, Swinnen LJ, Vose JM, Dwyer MA, Sundar H. NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. Journal Of The National Comprehensive Cancer Network 2019, 17: 650-661. PMID: 31200358, DOI: 10.6004/jnccn.2019.0029.Peer-Reviewed Original ResearchMeSH KeywordsAdultAftercareAntineoplastic Agents, ImmunologicalDrug Resistance, NeoplasmHumansImmunotherapy, AdoptiveLymphoma, FollicularLymphoma, Large B-Cell, DiffuseMedical OncologyNeoplasm Recurrence, LocalNeoplasm StagingPhosphoinositide-3 Kinase InhibitorsReceptors, Chimeric AntigenSignal TransductionUnited StatesConceptsDiffuse large B-cell lymphomaB-cell lymphomaRefractory follicular lymphomaFollicular lymphomaRefractory diffuse large B-cell lymphomaCAR T-cell therapyLarge B-cell lymphomaPoor clinical outcomeT-cell therapyNovel treatment optionsNCCN guidelinesClinical outcomesHodgkin's lymphomaTreatment optionsCommon subtypeHistologic transformationB cellsLymphomaTreatmentImportant updatesPatientsTherapySubtypesTFL
2015
Pediatric Brainstem Glioma Survival After Definitive Radiation Therapy With or Without Concurrent Chemotherapy: A Nationwide Comparison
Park H, Yeboa D, Lester-Coll N, Corso C, Mancini B, Bindra R, Roberts K, Yu J, Rutter C. Pediatric Brainstem Glioma Survival After Definitive Radiation Therapy With or Without Concurrent Chemotherapy: A Nationwide Comparison. International Journal Of Radiation Oncology • Biology • Physics 2015, 93: e504-e505. DOI: 10.1016/j.ijrobp.2015.07.1836.Peer-Reviewed Original ResearchThe Effect of Margin Status and Radiation Therapy on Survival in Adult Retroperitoneal Soft Tissue Sarcomas
Stahl J, Corso C, An Y, Aneja S, Rutter C, Park H, Mancini B, Yeboa D, Lester-Coll N, Han D, Roberts K. The Effect of Margin Status and Radiation Therapy on Survival in Adult Retroperitoneal Soft Tissue Sarcomas. International Journal Of Radiation Oncology • Biology • Physics 2015, 93: e638. DOI: 10.1016/j.ijrobp.2015.07.2175.Peer-Reviewed Original ResearchA report of metachronous orbital involvement by IgG4 disease treated successfully with low-dose radiation therapy
Rutter CE, Mancini BR, Roberts KB. A report of metachronous orbital involvement by IgG4 disease treated successfully with low-dose radiation therapy. Practical Radiation Oncology 2015, 6: 74-77. PMID: 26577005, DOI: 10.1016/j.prro.2015.09.007.Peer-Reviewed Original ResearchThe Role of Patient Factors, Cancer Characteristics, and Treatment Patterns in the Cost of Care for Medicare Beneficiaries with Breast Cancer
Xu X, Herrin J, Soulos PR, Saraf A, Roberts KB, Killelea BK, Wang SY, Long JB, Wang R, Ma X, Gross CP. The Role of Patient Factors, Cancer Characteristics, and Treatment Patterns in the Cost of Care for Medicare Beneficiaries with Breast Cancer. Health Services Research 2015, 51: 167-186. PMID: 26119176, PMCID: PMC4722219, DOI: 10.1111/1475-6773.12328.Peer-Reviewed Original ResearchConceptsBreast cancer careHospital referral regionsCancer careMedicare expendituresBreast cancerRadiation therapyTreatment factorsMean Medicare expendituresEnd Results-MedicareSpecific treatment modalitiesContribution of patientCost of careHighest spending quintilePatient factorsTreatment patternsTumor characteristicsCancer characteristicsTreatment modalitiesReferral regionsMedicare beneficiariesQuintilePatientsCancerCareTherapyHistorical trends of radiotherapy use in prevalent malignancies over 38 years in SEER
Yeboa D, Aneja S, Montana G, Roberts K, Yu J. Historical trends of radiotherapy use in prevalent malignancies over 38 years in SEER. Journal Of Radiation Oncology 2015, 4: 11-17. DOI: 10.1007/s13566-015-0182-y.Peer-Reviewed Original ResearchIntensity-modulated radiation therapyProstate cancerRadiation therapyEnd Results (SEER) databaseAmerican Joint CommitteeBreast cancer treatmentUse of RTInitial therapyMethodsThe SurveillanceRT receiptNonmetastatic patientsResults databaseCommon malignancyTherapy utilizationColorectal cancerLung cancerPrevalent malignancyCancer sitesRadiotherapy useHigh incidenceMedical treatmentJoint CommitteeDisease sitesPersistent decreaseTherapy
2014
Examining the Cost-Effectiveness of Radiation Therapy Among Older Women With Favorable-Risk Breast Cancer
Sen S, Wang SY, Soulos PR, Frick KD, Long JB, Roberts KB, Yu JB, Evans SB, Chagpar AB, Gross CP. Examining the Cost-Effectiveness of Radiation Therapy Among Older Women With Favorable-Risk Breast Cancer. Journal Of The National Cancer Institute 2014, 106: dju008. PMID: 24598714, PMCID: PMC3982782, DOI: 10.1093/jnci/dju008.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBrachytherapyBreast NeoplasmsComorbidityCost-Benefit AnalysisFemaleHealth ExpendituresHumansLife ExpectancyMedicareNeoplasm Recurrence, LocalNeoplasm StagingQuality of LifeQuality-Adjusted Life YearsRadiotherapy, Intensity-ModulatedRisk AssessmentRisk FactorsSampling StudiesSEER ProgramUnited StatesConceptsExternal beam radiation therapyIncremental cost-effectiveness ratioQuality-adjusted life yearsBreast cancerOlder womenRadiation therapyEnd Results-Medicare databaseRisk breast cancerBeam radiation therapyCost-effectiveness ratioNewer radiation therapy modalitiesQuality of lifeRadiation therapy modalitiesLocal recurrenceTrial criteriaRT modalityTherapy modalitiesLife yearsCancerIncremental costTherapyWomenBaseline stateNew modality
2012
Proton Radiation Therapy for Prostate Cancer in the Medicare Population: Patterns of Care and Comparison of Early Toxicity With Intensity Modulated Radiation Therapy
Yu J, Soulos P, Herrin J, Cramer L, Potosky A, Roberts K, Gross C. Proton Radiation Therapy for Prostate Cancer in the Medicare Population: Patterns of Care and Comparison of Early Toxicity With Intensity Modulated Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2012, 84: s13. DOI: 10.1016/j.ijrobp.2012.07.040.Peer-Reviewed Original Research
1999
135 Radiation dose selection in Hodgkin's disease patients with large mediastinal adenopathy treated with combined modality therapy
Elconin J, Roberts K, Vermont C, Rizzeri D, Clough R, Prosnitz L. 135 Radiation dose selection in Hodgkin's disease patients with large mediastinal adenopathy treated with combined modality therapy. International Journal Of Radiation Oncology • Biology • Physics 1999, 45: 216. DOI: 10.1016/s0360-3016(99)90153-0.Peer-Reviewed Original Research